Language: BG BG
← Back to results
Recruiting Phase 4 NCT06763731

Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery

Phase 4 – monitoring after market approval
Conditions: Ophthalmology

Sponsor: National Taiwan University Hospital

trial.available_in: БГ
Overview
Regular use of Systane COMPLETE in dry eye subjects before cataract surgery may optimize the ocular surface.
Description
STUDY OBJECTIVE:To evaluate the impact of predicted residual astigmatism in mixed dry eye patients regularly using Systane COMPLETE before cataract surgery. Hypothesis:Regular use of Systane COMPLETE in mixed dry eye subjects before cataract surgery may lead to more accurate astigmatism predictions. Objectives:To evaluate the Impact of predicted residual astigmatism in mixed dry eye patients regularly using Systane COMPLETE before cataract surgery. Inclusion Criteria The subjects aged 20-85 years, with normal cognitive function and capable of answering related questionnaires who require phacoemulsification and intraocular lens implantation under topical anaesthesia, are the eligible candidates. Exclusion Criteria Unable to answer the questions in the dry eye survey. Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts. Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect. Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin. Using dry eye medication at screening stage. Research Process V1 Screening (1-2 month before surgery) The subjects' demographic information will be collected. The pre-op assessments will be performed, and Informed Consent will be explained and endorsed during this visit. Systane COMPLETE MD1 bottle will be prescribed to all subjects who signed the ICF, with a dosing frequency of 1-2 drops q.i.d OU for 1-2 month. The LENSTAR 900 device (Haag-Streit Swiss) will be used to measure the biometry of the anterior cornea's keratometry at each visit. The measurement will be taken through five consecutive scans with only a few seconds of interval between each scan. The mean keratometry of these five scans will be used. Anterior corneal surface maps from Pentacam (OCULUS, Germany) will be used to identify patients with keratoconus or corneal irregularities at each visits. V2 Pre-operative (7 days before surgery) All participants will receive refractive examinations and take dry eye assessments. Repeat the same biometry measurement as the first visit. The final choice of the IOL for surgery is based on biometry measurements and Barrett Toric calculation. One eye per subject will be analysed. V3 Surgery day The participants will receive phacoemulsification and intraocular lens implantation. The participants with any intra-operative complication will be excluded from the study. To ensure compliance with the medication, it is required that the subjects return the used Systane COMPLETE bottle and medication diary at V3.
Who can participate
Inclusion Criteria: The subjects aged 20-85 years, with normal cognitive function and capable of answering related questionnaires who require phacoemulsification and intraocular lens implantation under topical anaesthesia, are the eligible candidates. Exclusion Criteria: 1. Unable to answer the questions in the dry eye survey. 2. Ocular trauma or ocular surgery in the planned surgical eye, active ocular infection, and obvious abnormalities in ocular surface or eyelid margins other than MGD cause decreased visual acuity other than cataracts. 3. Dry eye signs: Corneal Fluorescein Staining CFS (+) to exclude any corneal abnormalities or epithelial defect 4. Systemic drug use, including tetracycline derivatives, antihistamines, and isotretinoin. 5. Using dry eye medication at screening stage
Interventions
Systane COMPLETE
DRUG
Locations 1
Taiwan (1)
National Taiwan University Hospital
Taipei , Taiwan
Technical details
Status
Recruiting
Phase
Phase 4
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
20 Years
Maximum age
85 Years
Healthy volunteers
No
Start date
02.05.2024
Completion date
31.12.2027
Registry ID
NCT06763731
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.